Emergence and Characterization of a Ceftriaxone-Resistant *Neisseria gonorrhoeae* FC428 Clone Evolving Moderate-Level Resistance to Azithromycin in Shenzhen, China

Lulu Zhang^{1,2,*}Chi Zhang^{1,2,*}Yaling Zeng^{3,*}Yamei Li^{1,2}Shuhong Huang³Feng Wang³Junping Peng^{1,2}

¹NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China; ²Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; ³Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, People's Republic of China

*These authors contributed equally to this work

Correspondence: Feng Wang
Shenzhen Center for Chronic Disease Control, No. 2021, Buxin Road, Luohu District, Shenzhen, Guangdong, People's Republic of China
Tel/Fax +86-10-25504463
Email biowangfeng@163.com

Junping Peng
NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College; Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences, No. 6, Rongjing Eastern Street, BDA, Beijing, People's Republic of China
Tel/Fax +86-10-67878493
Email pengjp@hotmail.com

Abstract: We here described a ceftriaxone-resistant *Neisseria gonorrhoeae* FC428 clone (YL201) with moderate-level resistance to azithromycin in Shenzhen, South China in 2020. The NG-STAR type of YL201 is ST2238, containing a mosaic *penA*-60.001 allele, which is a typical characteristic of FC428 clone. YL201 harbours four copies of the 23S rRNA C2611T mutation, conferring moderate-level resistance to azithromycin. The MLST type is ST1600, identical with two *N. gonorrhoeae* FC428 clones identified in Hangzhou. Genome-wide phylogeny analysis demonstrates that YL201 is clustered with other FC428 clones from Hangzhou (South-east China) and Chengdu (South-west China). Isolates within this cluster have relatively higher MIC for ceftriaxone and display closely related MLST STs (ST1600 and ST7363) but are different from the ST of typical FC428 clone (ST1903). As ST1600 and ST7363 are common STs in Shenzhen, the further spread of FC428 clones may increase the severity of gonococcal resistance. In summary, identifying a multidrug-resistant (MDR) *N. gonorrhoeae* isolate in Shenzhen showed FC428 clones have undergone further transmission in China and presented more extensive and concerning antimicrobial resistance (AMR) characteristics during the spread.

Keywords: *Neisseria gonorrhoeae*, ceftriaxone, azithromycin, phylogeny, antimicrobial resistance

Introduction

With the emerging resistance of *N. gonorrhoeae* to nearly all antibiotics, effective antimicrobials for gonorrhoea have become increasingly scarce, including first-line dual therapy with ceftriaxone (CRO) and azithromycin (AZM) recommended by WHO.¹ To date, the MDR *N. gonorrhoeae* isolates have been reported in Ireland,² Denmark,³ UK⁴ and Australia.⁵ In China, *N. gonorrhoeae* isolates with decreased susceptibility or resistance to both CRO and AZM have been reported,⁶⁻⁸ and here in Guangdong Province (South China), we describe a ceftriaxone-resistant *N. gonorrhoeae* FC428 clone with a higher level of macrolide resistance than previously reported.

The patient was a heterosexual male in his late twenties. He visited the sexually transmitted diseases clinic in Shenzhen Center for Chronic Disease Control in August, 2020 with urethritis symptoms. He reported this was his third infection, and all infections were due to sexual intercourse with commercial sex workers. *N. gonorrhoeae* (isolate YL201) was cultured from urethral secretions.

Table 1 Phenotypic Characteristics and Molecular Characteristics of Isolates Related to the FC428 Clone

Isolate	Country	Patient Gender	Sexual Orientation	Sampling Site	MIC (mg/L)						PPNG	bla _{TEM} Type	Reference
					CRO	TET	SPT	AZM	CIP	PEN			
YL201	China	Male	Hetero	Urethral	0.75	4	12	12	32	1.5	Yes	I	This study
BJ16148	China	Male	Hetero	Urethral	0.5	4	16	0.25	>32	NA	NA	NA	[12]
GC185	China	NA	NA	Urethral	I	NA	NA	0.5	NA	NA	Yes	I35	[6]
GC250	China	Male	hetero	Urethral	0.5	NA	NA	2	NA	NA	Yes	I	[6]
SC18-25	China	Male	Hetero	Urethral	≥0.5	NA	16.0	0.5	≥16.0	2	No	No	[13]
SC18-26	China	Male	Hetero	Urethral	≥0.5	NA	16.0	1.0	≥16.0	≥8.0	Yes	I	[13]
SC18-68	China	Male	Hetero	Urethral	≥0.5	NA	16.0	0.5	≥16.0	4.0	No	No	[13]
SRRSH214	China	NA	NA	Urethral or vaginal	I	NA	NA	0.1	NA	NA	NA	NA	[7]
SRRSH229	China	NA	NA	Urethral or vaginal	I	NA	NA	0.3	NA	NA	NA	NA	[7]
SZ2017191	China	NA	NA	Urethral	0.5	8	16	0.5	16	I	NA	NA	[14]
FC428	Japan	Male	NA	Urethral	0.5	0.5	8	0.25	>32	>32	Yes	I35	[15]
FC460	Japan	Male	NA	Urethral	0.5	0.5	8	0.25	>32	>32	Yes	NA	[15]
FC498	Japan	Male	NA	Urethral	0.75	NA	8	0.5	>32	1.5	NO	NO	[16]
KU16054	Japan	Male	NA	Urethral	0.5	NA	8	0.19	>32	0.5	NO	NO	[16]
KM383	Japan	Male	NA	Urethral	0.5	NA	12	0.125	>32	I	NO	NO	[16]
A7846	Australia	Male	Hetero	Urethral	0.5	2	8	0.25	>32	≥32	Yes	NA	[17]
A7536	Australia	Male	Hetero	Urethral	0.5	4	8	0.25	>32	≥32	Yes	NA	[17]
GK124	Denmark	Male	Hetero	Urethral	0.5	NA	8	0.5	>32	>256	NA	NA	[3]
47707	Canada	Female	Hetero	NA	I	4	16	0.5	32	≥256	Yes	NA	[18]
IR72	Ireland	Male	Hetero	Urethral	0.5	0.5	16	0.38–0.5	>32	NA	NA	NA	[2]
A2543	Australia	Female	NA	NA	0.5	NA	NA	>256	NA	NA	NA	NA	[5]
H18-502	UK	Female	Hetero	Vaginal	I	2	8	0.5	>32	2	No	No	[4]
51742	Canada	Male	Hetero	Urethral	0.5	2	16	0.25	32	2	NA	NA	[19]

Abbreviations: CRO, ceftriaxone; TET, tetracycline; SPT, spectinomycin; AZM, azithromycin; CIP, ciprofloxacin; PEN, penicillin; PPNG, penicillinase producing *Neisseria gonorrhoeae*; NA, not available.

Figure 1 Maximum-likelihood tree based on 13,236 SNPs extracted from whole-genome sequences. FA1090 was placed as the outgroup. STs, antimicrobial resistance determinants and antimicrobial susceptibility are also shown. For YL201 and A2543, they contain four copies of the 23S rRNA C2611T and A2059G mutation respectively. Isolate YL201 described in this study is shown in red. The color coding of AMR phenotype and AMR-related alleles are indicated in the columns on the bottom left.

Abbreviations: R, resistance; S susceptibility; HLR, High-level resistance; WT, Wild type.

The minimal inhibitory concentrations (MICs) of the isolate were determined using E-TEST method, and the results were interpreted in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (www.eucast.org) interpretative criteria. YL201 showed resistance to CRO (MIC: 0.75 mg/L) and AZM (MIC: 12 mg/L), but was susceptible to spectinomycin (MIC: 12 mg/L) (Table 1).

Whole genome sequencing of YL201 was performed using Illumina HiSeq X Ten and Oxford Nanopore MinION sequencer. *N. gonorrhoeae* multiantigen sequence typing (NG-MAST), multilocus sequence typing (MLST) and *N. gonorrhoeae* Sequence Typing for Antimicrobial Resistance (NG-STAR) were confirmed using Sanger sequencing. The NG-MAST type was novel with *porB*-3101 and *thpB*-752. The MLST type was ST1600, identical with SRRSH214 and SRRSH229 identified in Hangzhou.⁷ Results of antimicrobial susceptibility testing showed that the three isolates with MLST_{ST1600} have higher MIC for ceftriaxone than most strains with MLST_{ST1903} (Table 1). This finding indicates that although isolates harbor identical *penA* mosaic allele, their MIC values may differ. Such variation can be explained by *penA*-60.001 allele

recombined into isolates with certain MLST types associated with CRO decreased susceptibility, and in this case, recombination events happening in MLST_{ST1600} isolates may contribute to a higher MIC value. According to our previous study,⁸ MLST_{ST7363} is associated with decreased ceftriaxone susceptibility. Moreover, phylogenetic analysis showed that MLST_{ST7363} isolates (SC18-68) were clustered with MLST_{ST1600} isolates, and that they share 6 identical loci with each other. Therefore, considering the genomic similarity between isolates with the two MLST STs, and the fact that MLST_{ST7363} is a common ST in Shenzhen, the expansion of *penA*-60.001 allele to MLST_{ST7363} isolates may have already happened and resulted in elevated MIC values. YL201 had the NG-STAR type of ST2238, containing a mosaic *penA*-60.001 allele with key resistance-mediating amino acid substitutions A311V and T483S, as well as G545S, I312M and V316T, which is typical characteristics of FC428 clone. YL201 has different NG-STAR type with SRRSH214 and SRRSH229 (ST2238 versus ST2208). The reason for this difference is that YL201 harbours four copies of the 23S rRNA C2611T mutation, while SRRSH214 and SRRSH229 with wild type 23S rRNA allele. Compared

Raw short-reads or draft genome assemblies of worldwide FC428-related strains were analysed to infer the phylogeny of YL201. A concatenate superset of SNPs relative to NCCP11945 was generated as previously described.⁹ Based on the genome-wide SNP sites, a maximum likelihood tree was built using PhyML 3.0¹⁰ and the substitution model was automatically selected using SMS (<http://www.atgc-montpellier.fr/phyml/>).¹¹ According to the phylogeny, YL201, SC18-68, SRRSH214 and SRRSH229 formed a clade (Figure 1), indicating FC428 clones originated from distinct regions have undergone further transmission in China. To date, all isolates within this clade have MLST

In conclusion, we have identified an MDR *N. gonorrhoeae* isolate in Shenzhen China with resistance to CRO and moderate-level resistance to AZM. The findings demonstrated that FC428 clones have undergone further transmission in China, and during the spread, they have presented more extensive and concerning AMR

characteristics. More importantly, as a major port with a large floating population, combined with our previous baseline data, we consider Shenzhen possesses the conditions for further transmission of FC428 clones, thus increasing the severity of gonococcal resistance. Therefore, regional surveillance should be highlighted to understand the transmission of emerging gonococcal drug-resistant clones.

Ethics Approval and Consent to Participate

This study was conducted in accordance with the Declaration of Helsinki and obtained approval from Medical Ethics Committee at the Shenzhen Center for Chronic Disease Control (approval number SZCCC-2021-008-01-PJ). Written informed consent was provided by the patient to allow the case details to be published.

Funding

This study was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-3-021); the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-PT310-004); the National Science and Technology Infrastructure of China (Project No. National Pathogen Resource Center-NPRC-32); and the Sanming Project of Medicine in Shenzhen (SZSM201611077).

Disclosure

The authors report no conflicts of interest in this work.

References

- Unemo M, Lahra MM, Cole M, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. *Sex Health*. 2019;16(5):412–425. doi:10.1071/SH19023
- Golparian D, Rose L, Lynam A, et al. Multidrug-resistant *Neisseria gonorrhoeae* isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. *Eur Surveill*. 2018;23(47). doi:10.2807/1560-7917.ES.2018.23.47.1800617.
- Terkelsen D, Tolstrup J, Johnsen CH, et al. Multidrug-resistant *Neisseria gonorrhoeae* infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. *Eur Surveill*. 2017;22(42). doi:10.2807/1560-7917.ES.2017.22.42.17-00659.
- Eyre DW, Town K, Street T, et al. Detection in the United Kingdom of the *Neisseria gonorrhoeae* FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. *Eur Surveill*. 2019;24(10). doi:10.2807/1560-7917.ES.2019.24.10.1900147.
- Whiley DM, Jennison A, Pearson J, Lahra MM. Genetic characterisation of *Neisseria gonorrhoeae* resistant to both ceftriaxone and azithromycin. *Lancet Infect Dis*. 2018;18(7):717–718. doi:10.1016/S1473-3099(18)30340-2
- Yuan Q, Li Y, Xiu L, et al. Identification of multidrug-resistant *Neisseria gonorrhoeae* isolates with combined resistance to both ceftriaxone and azithromycin, China, 2017–2018. *Emerg Microbes Infect*. 2019;8(1):1546–1549. doi:10.1080/22221751.2019.1681242
- Yan J, Chen Y, Yang F, et al. High percentage of the ceftriaxone-resistant *Neisseria gonorrhoeae* FC428 clone among isolates from a single hospital in Hangzhou, China. *J Antimicrob Chemother*. 2021;76(4):936–939. doi:10.1093/jac/dkaa526
- Li Y, Li Y, Xiu L, et al. Typing of *Neisseria Gonorrhoeae* isolates in Shenzhen, China from 2014–2018 reveals the shift of genotypes associated with antimicrobial resistance. *Antimicrob Agents Chemother*. 2021;65(5). doi:10.1128/AAC.02311-20.
- Peng JP, Yin YP, Chen SC, et al. A whole-genome sequencing analysis of *Neisseria gonorrhoeae* Isolates in China: an observational study. *EClinicalMedicine*. 2019;7:47–54. doi:10.1016/j.eclinm.2019.01.010
- Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol*. 2010;59(3):307–321. doi:10.1093/sysbio/syq010
- Lefort V, Longueville JE, Gascuel O. SMS: smart model selection in PhyML. *Mol Biol Evol*. 2017;34(9):2422–2424. doi:10.1093/molbev/msx149
- Chen SC, Han Y, Yuan LF, Zhu XY, Yin YP. Identification of internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain FC428, China. *Emerg Infect Dis*. 2019;25(7):1427–1429. doi:10.3201/eid2507.190172
- Wang H, Wang Y, Yong G, et al. Emergence and genomic characterization of the ceftriaxone-resistant *Neisseria gonorrhoeae* FC428 clone in Chengdu, China. *J Antimicrob Chemother*. 2020;75(9):2495–2498. doi:10.1093/jac/dkaa123
- Zhang C, Wang F, Zhu C, et al. Determining antimicrobial resistance profiles and identifying novel mutations of *Neisseria gonorrhoeae* genomes obtained by multiplexed MinION sequencing. *Sci China Life Sci*. 2020;63(7):1063–1070. doi:10.1007/s11427-019-1558-8
- Nakayama S, Shimuta K, Furubayashi K, Kawahata T, Unemo M, Ohnishi M. New ceftriaxone- and multidrug-resistant *Neisseria gonorrhoeae* strain with a novel mosaic penA gene isolated in Japan. *Antimicrob Agents Chemother*. 2016;60(7):4339–4341. doi:10.1128/AAC.00504-16
- Lee K, Nakayama SI, Osawa K, et al. Clonal expansion and spread of the ceftriaxone-resistant *Neisseria gonorrhoeae* strain FC428, identified in Japan in 2015, and closely related isolates. *J Antimicrob Chemother*. 2019;74(7):1812–1819. doi:10.1093/jac/dkz129
- Lahra MM, Martin I, Demczuk W, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain. *Emerg Infect Dis*. 2018;24(4). doi:10.3201/eid2404.171873.
- Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-resistant *Neisseria gonorrhoeae*, Canada, 2017. *Emerg Infect Dis*. 2018;24(2):381–383. doi:10.3201/eid2402.171756
- Berenger BM, Demczuk W, Gratrix J, Pabbaraju K, Smyczek P, Martin I. Genetic characterization and enhanced surveillance of ceftriaxone-resistant *Neisseria gonorrhoeae* strain, Alberta, Canada, 2018. *Emerg Infect Dis*. 2019;25(9):1660–1667. doi:10.3201/eid2509.190407

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>